QuickLinks -- Click here to rapidly navigate through this document

As filed with the Securities and Exchange Commission on October 5, 2004.

Registration No. 333-            



SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933


Theravance, Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)
  2834
(Primary Standard Industrial
Classification Code Number)
  94-3265960
(I.R.S. Employer
Identification Number)

901 Gateway Boulevard
South San Francisco, California 94080
(650) 808-6000
(Address, including zip code, and telephone number, including
area code, of registrant's principal executive offices)


Rick E Winningham
Chief Executive Officer
901 Gateway Boulevard
South San Francisco, California 94080
(650) 808-6000
(Name, address, including zip code, and telephone number, including area code, of agent for service)




Copies to:
Robert V. Gunderson, Jr., Esq.
Jay K. Hachigian, Esq.
David T. Young, Esq.
John F. Dietz, Esq.
Gunderson Dettmer Stough
Villeneuve Franklin & Hachigian, LLP
155 Constitution Drive
Menlo Park, CA 94025
(650) 321-2400
  Alan F. Denenberg, Esq.
Martin A. Wellington, Esq.
Davis Polk & Wardwell
1600 El Camino Real
Menlo Park, CA 94025
(650) 752-2000

Approximate date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this registration statement.


                 If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, check the following box.    / /

                 If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    /X/    333-116384

                 If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    / /

                 If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    / /

                 If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box.    / /


CALCULATION OF REGISTRATION FEE


Title of Each Class of
Securities to be Registered

  Amount to be
Registered(1)

  Proposed Maximum
Aggregate
Offering Price
Per Share(2)

  Proposed Maximum
Aggregate
Offering Price(2)

  Amount of
Registration Fee(3)


Common Stock, $.01 par value   1,092,500   $16.00   $17,480,000   $2,214.72

(1)
Includes 142,500 shares that the Underwriters have the option to purchase to cover over-allotments, if any.

(2)
Based on the public offering price.

(3)
This amount has been paid and is in addition to the registration fee of $12,122.66 also paid to register 5,980,000 shares to be sold to the public at $16.00 per share pursuant to Registration Statement No. 333-116384.





EXPLANATORY NOTE

              This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The contents of the Registration Statement on Form S-1 (Reg. No. 333-116384) filed by Theravance, Inc. (the "Company") with the Securities and Exchange Commission (the "Commission") on June 10, 2004, as amended, including the exhibits thereto, and declared effective by the Commission on October 4, 2004, are incorporated herein by reference. This Registration Statement also contains Exhibits 5.1 and 23.1.


UNDERTAKING

              The registrant hereby undertakes and agrees to pay the registration fee for the securities registered hereunder as soon as practicable (but in any event no later than the close of the next business day following the filing of the Registration Statement). The registrant has given irrevocable wiring instructions to its bank to wire the registration fee to the Commission immediately and it will confirm receipt of such instructions by the bank during regular business hours. Registrant will have sufficient funds in its account to cover the amount of the filing fee.



SIGNATURES

              Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California on October 5, 2004.

    THERAVANCE, INC.

 

 

By:

 

*

Rick E Winningham
Chief Executive Officer

              Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

Name
  Title
  Date

 

 

 

 

 
*
Rick E Winningham
  Chief Executive Officer and Director (principal executive officer)   October 5, 2004

*

Marty Glick

 

Chief Financial Officer (principal financial and accounting officer)

 

October 5, 2004

*

P. Roy Vagelos

 

Director

 

October 5, 2004

*

Julian C. Baker

 

Director

 

October 5, 2004

*

Jeffrey M. Drazan

 

Director

 

October 5, 2004

*

Robert V. Gunderson, Jr.

 

Director

 

October 5, 2004

*

Arnold J. Levine

 

Director

 

October 5, 2004

*

Ronn C. Loewenthal

 

Director

 

October 5, 2004

*

Michael Mullen

 

Director

 

October 5, 2004

*

William H. Waltrip

 

Director

 

October 5, 2004

*

George M. Whitesides

 

Director

 

October 5, 2004

*

William D. Young

 

Director

 

October 5, 2004

*By:

/s/  
BRADFORD J. SHAFER      
Bradford J. Shafer
Attorney-in-fact

 

 

 

 


EXHIBIT INDEX

Exhibit No.
  Exhibit Index
5.1   Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigan, LLP

23.2

 

Consent of Independent Registered Public Accounting Firm

24.1*

 

Power of Attorney of certain directors and officers of the Registrant (included on page II-8 of the Registration Statement on Form S-1, 333-116384)

*
Incorporated by reference to the Company's Registration Statement on Form S-1, as amended, Registration No. 333-116384.



QuickLinks

EXPLANATORY NOTE
UNDERTAKING
SIGNATURES
EXHIBIT INDEX

QuickLinks -- Click here to rapidly navigate through this document


EXHIBIT 5.1

October 4, 2004

Theravance, Inc.
901 Gateway Boulevard
South San Francisco, CA 94080

                      Re:    462(b) Registration Statement on Form S-1

Ladies and Gentlemen:

              At your request, we have examined the Registration Statement on Form S-1 to which this letter is attached as Exhibit 5.1 (the "462(b) Registration Statement") filed by Theravance, Inc. (the "Company") with the Securities and Exchange Commission ("Commission") pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended ("Securities Act") and relating to the registration under the Securities Act of an additional 1,092,500 shares of the Company's common stock, par value $0.01 per share (the "Additional Shares"). The Rule 462(b) Registration Statement to be used for the offer and sale of the Additional Shares is filed with the Commission in connection with the offering described in the Registration Statement on Form S-1 (Registration No. 333-116384) filed with the Commission on June 10, 2004, as amended, which was declared effective by the Commission on October 4, 2004.

              We are familiar with the proceedings taken by the Company in connection with the authorization of the Additional Shares. We have examined such documents, records and matters of law as we have deemed necessary for purposes of this opinion. In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity to originals of all documents submitted to us as certified or reproduced copies.

              Based upon the foregoing, and assuming, without further inquiry that the consideration for the Additional Shares to be issued will be received prior to the issuance thereof, and when the 462(b) Registration Statement becomes effective, upon which our opinions are expressly conditioned, we opine as follows:

              If, as and when such shares of Common Stock have been issued and sold in conformity with and pursuant to the 462(b) Registration Statement, such Additional Shares will be legally issued, fully paid and non-assessable.

              We consent to the filing of this opinion as an exhibit to the 462(b) Registration Statement.


 

 

Very truly yours,

 

 

/s/  
GUNDERSON DETTMER STOUGH VILLENEUVE FRANKLIN & HACHIGIAN, LLP      

 

 

GUNDERSON DETTMER STOUGH VILLENEUVE FRANKLIN & HACHIGIAN, LLP



QuickLinks


QuickLinks -- Click here to rapidly navigate through this document


Exhibit 23.2


Consent of Independent Registered Public Accounting Firm

              We consent to the incorporation by reference in the Registration Statement on Form S-1 filed on October 5, 2004 of Theravance, Inc. of our report dated May 21, 2004 (except for Note 14 and paragraph 39 of Note 2, as to which the dates are May 27, 2004 and September 27, 2004, respectively) with respect to the consolidated financial statements of Theravance, Inc. included in Amendment No. 7 to its Registration Statement (Form S-1 No. 333-116384) and related Prospectus for the registration of shares of its common stock.

/s/  ERNST & YOUNG LLP      

Palo Alto, California
October 4, 2004




QuickLinks

Consent of Independent Registered Public Accounting Firm